🇺🇸 FDA
Patent

US 10092637

Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes

granted A61KA61K2039/5258A61K2039/53

Quick answer

US patent 10092637 (Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/5258, A61K2039/53, A61K2039/57, A61K2039/575